Prescribing the right medication, at the right dose, to the right patient is the goal of every physician. Pharmacogenomic information is an emerging tool that can be used to deliver precision medicine. In this review, we discuss the pharmacogenomics of available PPIs, racial differences of CYP2C19 and how PPI pharmacogenomics affects the treatment of common gastrointestinal diseases. We also provide practical guidance on when to order pharmacogenomic testing, which test to order, and how to modify treatment based on published guidelines.
Keywords: Gastroesophageal reflux disease; Helicobacter pylori; Pharmacogenomics; Proton pump inhibitors.
© 2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC part of Springer Nature.